OncoMatch/Clinical Trials/NCT06412952

68Ga-NOTA-RM26 PET/CT in Glioma Patients

Is NCT06412952 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies 68Ga-RM26 for glioma.

Early Phase 1RecruitingPeking Union Medical College HospitalNCT06412952Data as of May 2026

Treatment: 68Ga-RM26 — The aim of this study was to investigate the value of 68Ga-NOTA-RM26, an antagonist targeting gastrin-releasing peptide receptor (GRPR) PET tracer, in the diagnosis of high WHO grade glioma and prediction the grade of glioma using positron-emission tomography/computed tomography (PET/CT).

Check if I qualify

Extracted eligibility criteria

Cancer type

Glioblastoma

Prior therapy

No prior treatment (treatment-naive required)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify